ALX Oncology (ALXO) Appoints Alan Sandler to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil falls on weaker demand outlook and higher US stocks
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
August 6, 2024 4:01 PM EDT- Dr. Sandler brings more than 30 years of experience and leadership in oncology and drug development -
- Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., will leave board to focus on ALX leadership responsibilities as Companys clinical program advances -
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (ALX Oncology or the Company) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced today the appointment of Alan Sandler, M.D., to its Board of Directors effective... More
